These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

640 related items for PubMed ID: 27437883

  • 41. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MS.
    Circulation; 2019 Nov 05; 140(19):1569-1577. PubMed ID: 31474116
    [Abstract] [Full Text] [Related]

  • 42. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Widlansky ME, Puppala VK, Suboc TM, Malik M, Branum A, Signorelli K, Wang J, Ying R, Tanner MJ, Tyagi S.
    Vasc Med; 2017 Jun 05; 22(3):189-196. PubMed ID: 28145158
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT, Chang KC, Li CY, Wu JS.
    Cardiovasc Diabetol; 2016 Mar 01; 15():41. PubMed ID: 26932742
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N.
    Prim Care Diabetes; 2019 Jun 01; 13(3):204-211. PubMed ID: 30713085
    [Abstract] [Full Text] [Related]

  • 50. [Gliptins, cardiovascular safety and congestive heart failure: state of the art after TECOS].
    Scheen AJ.
    Rev Med Suisse; 2015 Aug 26; 11(483):1526-31. PubMed ID: 26502578
    [Abstract] [Full Text] [Related]

  • 51. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators.
    N Engl J Med; 2013 Oct 03; 369(14):1317-26. PubMed ID: 23992601
    [Abstract] [Full Text] [Related]

  • 52. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
    Guthrie R.
    Postgrad Med; 2020 May 03; 132(4):314-319. PubMed ID: 32164494
    [Abstract] [Full Text] [Related]

  • 53. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ, Choi J, Lee J, Bae JH, An JH, Kim HY, Yoo HJ, Seo JA, Kim NH, Choi KM, Baik SH, Kim SG, Kim NH.
    Cardiovasc Diabetol; 2019 Mar 11; 18(1):28. PubMed ID: 30857540
    [Abstract] [Full Text] [Related]

  • 54. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
    Chen DY, Wang SH, Mao CT, Tsai ML, Lin YS, Chou CC, Wen MS, Wang CC, Hsieh IC, Hung KC, Chen TH.
    Int J Cardiol; 2015 Feb 15; 181():200-6. PubMed ID: 25528312
    [Abstract] [Full Text] [Related]

  • 55. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
    Liu X, Men P, Wang Y, Zhai S, Liu G.
    Lipids Health Dis; 2016 Nov 23; 15(1):204. PubMed ID: 27881129
    [Abstract] [Full Text] [Related]

  • 56. Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
    Pollack PS, Chadwick KD, Smith DM, Billger M, Hirshberg B, Iqbal N, Boulton DW.
    Cardiovasc Diabetol; 2017 Sep 13; 16(1):113. PubMed ID: 28903775
    [Abstract] [Full Text] [Related]

  • 57. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
    Chang CH, Chang YC, Lin JW, Caffrey JL, Wu LC, Lai MS, Chuang LM.
    Int J Cardiol; 2016 Oct 01; 220():14-20. PubMed ID: 27389437
    [Abstract] [Full Text] [Related]

  • 58. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
    Marx N, Kolkailah AA, Rosenstock J, Johansen OE, Cooper ME, Alexander JH, Toto RD, Wanner C, Espeland MA, Mattheus M, Schnaidt S, Perkovic V, Gollop ND, McGuire DK.
    JAMA Cardiol; 2024 Feb 01; 9(2):134-143. PubMed ID: 38170502
    [Abstract] [Full Text] [Related]

  • 59. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F.
    Lancet Diabetes Endocrinol; 2017 May 01; 5(5):341-354. PubMed ID: 28385659
    [Abstract] [Full Text] [Related]

  • 60. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F.
    Am Heart J; 2011 Oct 01; 162(4):620-626.e1. PubMed ID: 21982652
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.